A citation-based method for searching scientific literature

Joji Nagasaki, Yosuke Togashi. Int Immunol 2022
Times Cited: 2







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Low Lymphocyte-to-Monocyte Ratios Are Associated with Poor Overall Survival in Anaplastic Thyroid Carcinoma Patients.
Jonghwa Ahn, Eyun Song, Hye-Seon Oh, Dong Eun Song, Won Gu Kim, Tae Yong Kim, Won Bae Kim, Young Kee Shong, Min Ji Jeon. Thyroid 2019
26
50


Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer.
Janice M Mehnert, Andrea Varga, Marcia S Brose, Rahul R Aggarwal, Chia-Chi Lin, Amy Prawira, Filippo de Braud, Kenji Tamura, Toshihiko Doi, Sarina A Piha-Paul,[...]. BMC Cancer 2019
85
50

FOXP1 abnormalities in lymphoma: translocation breakpoint mapping reveals insights into deregulated transcriptional control.
Alison Goatly, Chris M Bacon, Shotaro Nakamura, Hongtao Ye, Insun Kim, Philip J Brown, Agnès Ruskoné-Fourmestraux, Pascale Cervera, Berthold Streubel, Alison H Banham,[...]. Mod Pathol 2008
53
50

Alternative splicing and gene duplication in the evolution of the FoxP gene subfamily.
M Emília Santos, Alekos Athanasiadis, Alexandre B Leitão, Louis DuPasquier, Elio Sucena. Mol Biol Evol 2011
38
50

T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma.
B Streubel, U Vinatzer, A Lamprecht, M Raderer, A Chott. Leukemia 2005
252
50

Epigenetic control of Foxp3 in intratumoral T-cells regulates growth of hepatocellular carcinoma.
Qin Liu, Fang Du, Wei Huang, Xiaoyi Ding, Zhongmin Wang, Fuhua Yan, Zhiyuan Wu. Aging (Albany NY) 2019
9
50

Molecular networks of FOXP family: dual biologic functions, interplay with other molecules and clinical implications in cancer progression.
Ju-Ha Kim, Jisung Hwang, Ji Hoon Jung, Hyo-Jung Lee, Dae Young Lee, Sung-Hoon Kim. Mol Cancer 2019
42
50

Tumor-associated lymphocytes and increased FoxP3+ regulatory T cell frequency correlate with more aggressive papillary thyroid cancer.
Jena D French, Zachary J Weber, Deborah L Fretwell, Sherif Said, Joshua P Klopper, Bryan R Haugen. J Clin Endocrinol Metab 2010
104
50

Metabolism of Dendritic Cells in Tumor Microenvironment: For Immunotherapy.
Xin Peng, Youe He, Jun Huang, Yongguang Tao, Shuang Liu. Front Immunol 2021
21
50

Downregulation of FOXP2 promoter human hepatocellular carcinoma cell invasion.
Xia Yan, Huiling Zhou, Tingting Zhang, Pan Xu, Shusen Zhang, Wei Huang, Linlin Yang, Xingxing Gu, Runzhou Ni, Tianyi Zhang. Tumour Biol 2015
27
50

Long non-coding RNA FOXP4-AS1 is an unfavourable prognostic factor and regulates proliferation and apoptosis in colorectal cancer.
Juan Li, Yifan Lian, Changsheng Yan, Zeling Cai, Jie Ding, Zhonghua Ma, Peng Peng, Keming Wang. Cell Prolif 2017
69
50

Epidemiology of Thyroid Cancer: A Review of the National Cancer Database, 2000-2013.
Evan Olson, Grant Wintheiser, Katrina M Wolfe, Jonathan Droessler, Peter T Silberstein. Cureus 2019
54
50


Programmed death-1+ T cells and regulatory T cells are enriched in tumor-involved lymph nodes and associated with aggressive features in papillary thyroid cancer.
Jena D French, Gregory R Kotnis, Sherif Said, Christopher D Raeburn, Robert C McIntyre, Joshua P Klopper, Bryan R Haugen. J Clin Endocrinol Metab 2012
77
50

Fox transcription factors: from development to disease.
Maria L Golson, Klaus H Kaestner. Development 2016
176
50

Immune Cell Confrontation in the Papillary Thyroid Carcinoma Microenvironment.
Zhenyu Xie, Xin Li, Yuzhen He, Song Wu, Shiyue Wang, Jianjian Sun, Yuchen He, Yu Lun, Jian Zhang. Front Endocrinol (Lausanne) 2020
31
50

The role of anlotinib-mediated EGFR blockade in a positive feedback loop of CXCL11-EGF-EGFR signalling in anaplastic thyroid cancer angiogenesis.
Juyong Liang, Zhijian Jin, Jie Kuang, Haoran Feng, Qiwu Zhao, Zheyu Yang, Ling Zhan, Baiyong Shen, Jiqi Yan, Wei Cai,[...]. Br J Cancer 2021
6
50

Association of THADA, FOXP4, GPRC6A/RFX6 genes and 8q24 risk alleles with prostate cancer in Northern Chinese men.
Xing-Hui Li, Yong Xu, Kuo Yang, Jian-Jian Shi, Xiao Zhang, Fang Yang, Huiping Yuan, Xiaoquan Zhu, Yu-Hong Zhang, Jian-Ye Wang,[...]. J BUON 2015
8
50

Thyroid Cancer: Risk-Stratified Management and Individualized Therapy.
Friedhelm Raue, Karin Frank-Raue. Clin Cancer Res 2016
78
50

Circulating thyroid cancer biomarkers: Current limitations and future prospects.
Alexander M Nixon, Xeni Provatopoulou, Eleni Kalogera, George N Zografos, Antonia Gounaris. Clin Endocrinol (Oxf) 2017
24
50

Immune and Inflammatory Cells in Thyroid Cancer Microenvironment.
Silvia Martina Ferrari, Poupak Fallahi, Maria Rosaria Galdiero, Ilaria Ruffilli, Giusy Elia, Francesca Ragusa, Sabrina Rosaria Paparo, Armando Patrizio, Valeria Mazzi, Gilda Varricchi,[...]. Int J Mol Sci 2019
90
50

Thyroid cancer incidence trends by histology in 25 countries: a population-based study.
Adalberto Miranda-Filho, Joannie Lortet-Tieulent, Freddie Bray, Bochen Cao, Silvia Franceschi, Salvatore Vaccarella, Luigino Dal Maso. Lancet Diabetes Endocrinol 2021
78
50

The evolution of Fox genes and their role in development and disease.
Sridhar Hannenhalli, Klaus H Kaestner. Nat Rev Genet 2009
430
50

MicroRNA-338-3p inhibits cell proliferation in hepatocellular carcinoma by target forkhead box P4 (FOXP4).
Gang Wang, Yubei Sun, Yifu He, Chushu Ji, Bing Hu, Yuping Sun. Int J Clin Exp Pathol 2015
51
50

Strong expression of the neuronal transcription factor FOXP2 is linked to an increased risk of early PSA recurrence in ERG fusion-negative cancers.
Laura Stumm, Lia Burkhardt, Stefan Steurer, Ronald Simon, Meike Adam, Andreas Becker, Guido Sauter, Sarah Minner, Thorsten Schlomm, Hüseyin Sirma,[...]. J Clin Pathol 2013
27
50

Knockdown of FOXP1 promotes the development of lung adenocarcinoma.
Hua Sheng, Xiangyang Li, Yi Xu. Cancer Biol Ther 2019
15
50

Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma.
Priyanka C Iyer, Ramona Dadu, Maria Gule-Monroe, Naifa L Busaidy, Renata Ferrarotto, Mouhammed Amir Habra, Mark Zafereo, Michelle D Williams, G Brandon Gunn, Horiana Grosu,[...]. J Immunother Cancer 2018
101
50

FOXP3 is a novel transcriptional repressor for the breast cancer oncogene SKP2.
Tao Zuo, Runhua Liu, Huiming Zhang, Xing Chang, Yan Liu, Lizhong Wang, Pan Zheng, Yang Liu. J Clin Invest 2007
187
50

The Dominant Role of Forkhead Box Proteins in Cancer.
Duc-Hiep Bach, Nguyen Phuoc Long, Thi-Thu-Trang Luu, Nguyen Hoang Anh, Sung Won Kwon, Sang Kook Lee. Int J Mol Sci 2018
41
50


Members of FOX family could be drug targets of cancers.
Jinhua Wang, Wan Li, Ying Zhao, De Kang, Weiqi Fu, Xiangjin Zheng, Xiaocong Pang, Guanhua Du. Pharmacol Ther 2018
27
50

Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab.
Michael S van der Veer, Michel de Weers, Berris van Kessel, Joost M Bakker, Shulamiet Wittebol, Paul W H I Parren, Henk M Lokhorst, Tuna Mutis. Haematologica 2011
162
50

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX.
Meletios A Dimopoulos, Jesus San-Miguel, Andrew Belch, Darrell White, Lotfi Benboubker, Gordon Cook, Merav Leiba, James Morton, P Joy Ho, Kihyun Kim,[...]. Haematologica 2018
147
50

Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma.
Jia Ruan, Peter Martin, Bijal Shah, Stephen J Schuster, Sonali M Smith, Richard R Furman, Paul Christos, Amelyn Rodriguez, Jakub Svoboda, Jessica Lewis,[...]. N Engl J Med 2015
174
50

Impact of lenalidomide on the functional properties of human mesenchymal stromal cells.
Manja Wobus, Gwendolin Benath, Ruben A Ferrer, Rebekka Wehner, Marc Schmitz, Lorenz C Hofbauer, Martina Rauner, Gerhard Ehninger, Martin Bornhäuser, Uwe Platzbecker. Exp Hematol 2012
26
50

Lenalidomide induced secondary Acute Lymphoblastic Leukemia in a Multiple Myeloma patient: A case-report.
Dr Saqib Raza Khan, Dr Muhammad Tariq, Dr Sidra Malik Fayyaz, Salman Muhammad Soomar, Dr Munira Moosajee. Leuk Res Rep 2022
3
50

Rituximab: mechanism of action.
George J Weiner. Semin Hematol 2010
491
50

Lenalidomide enhances MOR202-dependent macrophage-mediated effector functions via the vitamin D pathway.
Leonhard Busch, Dimitrios Mougiakakos, Maike Büttner-Herold, Miriam J Müller, Dietrich A Volmer, Christian Bach, Mario Fabri, Jörg T Bittenbring, Frank Neumann, Rainer Boxhammer,[...]. Leukemia 2018
28
50


Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma.
Thomas M Habermann, Izidore S Lossos, Glen Justice, Julie M Vose, Peter H Wiernik, Kyle McBride, Kenton Wride, Annette Ervin-Haynes, Kenichi Takeshita, Dennis Pietronigro,[...]. Br J Haematol 2009
212
50

Understanding the Role of T-Cells in the Antimyeloma Effect of Immunomodulatory Drugs.
Criselle D'Souza, H Miles Prince, Paul J Neeson. Front Immunol 2021
12
50

A Cereblon Modulator CC-885 Induces CRBN- and p97-Dependent PLK1 Degradation and Synergizes with Volasertib to Suppress Lung Cancer.
Lifeng Li, Wenhua Xue, Zhibo Shen, Jie Liu, Min Hu, Zhenyong Cheng, Yuxing Wang, Yulu Chen, Hao Chang, Yingyi Liu,[...]. Mol Ther Oncolytics 2020
14
50


RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma.
Pier Luigi Zinzani, Thomas Rodgers, Dario Marino, Maurizio Frezzato, Anna Maria Barbui, Claudia Castellino, Erika Meli, Nathan H Fowler, Gilles Salles, Bruce Feinberg,[...]. Clin Cancer Res 2021
10
50

Thalidomide inhibits epidermal growth factor-induced cell growth in mouse and human monocytic leukemia cells via Ras inactivation.
Abu Shadat M Noman, Naoki Koide, Imtiaz I-E Khuda, Jargalsaikhan Dagvadorj, Gantsetseg Tumurkhuu, Yoshikazu Naiki, Takayuki Komatsu, Tomoaki Yoshida, Takashi Yokochi. Biochem Biophys Res Commun 2008
11
50

CC-122 immunomodulatory effects in refractory patients with diffuse large B-cell lymphoma.
Carolina Cubillos-Zapata, Raúl Cordoba, José Avendaño-Ortiz, Cristina Arribas-Jiménez, Enrique Hernández-Jiménez, Víctor Toledano, Teresa Villaescusa, Víctor Moreno, Eduardo López-Collazo. Oncoimmunology 2016
15
50

Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML).
Melita Kenealy, Nigel Patton, Robin Filshie, Andrew Nicol, Shir-Jing Ho, Mark Hertzberg, Tony Mills, Ian Prosser, Emma Link, Linda Cowan,[...]. Leuk Lymphoma 2017
11
50

A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.
T E Witzig, G S Nowakowski, T M Habermann, A Goy, F J Hernandez-Ilizaliturri, A Chiappella, U Vitolo, N Fowler, M S Czuczman. Ann Oncol 2015
66
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.